Filtered By:
Infectious Disease: Pandemics
Drug: Aspirin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 60 results found since Jan 2013.
Prophylactic anticoagulants for non-hospitalised people with COVID-19
CONCLUSIONS: We found low- to moderate-certainty evidence from five RCTs that prophylactic anticoagulants result in little or no difference in major bleeding, DVT, need for hospitalisation, or adverse events when compared with placebo or no treatment in non-hospitalised people with COVID-19. Low-certainty evidence indicates that prophylactic anticoagulants may result in little or no difference in all-cause mortality when compared with placebo or no treatment, but moderate-certainty evidence indicates that prophylactic anticoagulants probably reduce the incidence of VTE and PE. Low-certainty evidence suggests that comparing...
Source: Cochrane Database of Systematic Reviews - August 17, 2023 Category: General Medicine Authors: Brena C Santos Ronald Lg Flumignan Vinicius T Civile Álvaro N Atallah Luis Cu Nakano Source Type: research
Association between metabolic syndrome and colorectal cancer incidence and all-cause mortality: a hospital-based observational study
CONCLUSION: Compared with 1-2 components, subjects with 3-4 MetS components are at greater risk of CRC and death at follow-up. This study also demonstrates the risks for CRC and all-cause mortality in certain subgroups of individuals with 3-4 MetS components compared to 1-2 components. These findings may help clinicians on the CRC risk stratification according to individuals' characteristics, as well as to optimize the strategy of MetS surveillance and control in order to prevent CRC.PMID:36368935 | DOI:10.1186/s12876-022-02505-5
Source: Cancer Control - November 11, 2022 Category: Cancer & Oncology Authors: Kuan-Chih Chung Sin-Ei Juang Hong-Hwa Chen Kung-Chuan Cheng Kuen-Lin Wu Ling-Chiao Song Ko-Chao Lee Source Type: research
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00299-5. doi: 10.1016/S2213-2600(22)00299-5. Online ahead of print.ABSTRACTBACKGROUND: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) outpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin for prevention of disease progression in community patients with COVID-19.METHODS: The ACT outpatient, open-label, 2 × 2 factorial, randomised, controlled trial, was done at 48 clinical sites in 11 countries. Patients in th...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Wadea M Tarhuni Mohamed Hassany Anna Kontsevaya William Harper Sanjib Kumar Sharma Patricio Lopez-Jaramillo Antonio L D Source Type: research
Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS)
CONCLUSIONS: In this large international cohort, pre-hospital use of ASA was associated with a lower hazard for death in hospitalized patients with COVID-19. Randomized controlled trials may be warranted to assess the utility of pre-hospital use of ASA.PMID:36153214 | DOI:10.1016/j.arbres.2022.07.017
Source: Archivos de Bronconeumologia - September 24, 2022 Category: Respiratory Medicine Authors: Amos Lal Juan Pablo Domecq Garces Vikas Bansal Aysun Tekin Simon Zec Ashish K Khanna Matthew A Warner Amy B Christie Rodrigo Cartin-Ceba Valerie M Banner-Goodspeed Donna Lee Armaignac Sreekanth R Cheruku Umamaheswara Raju Yasir Tarabichi Joshua L Denson V Source Type: research
Top 20 Research Studies of 2021 for Primary Care Physicians
This article summarizes the top 20 research studies of 2021 identified as POEMs (patient-oriented evidence that matters) that did not address the COVID-19 pandemic. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prevent adverse cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and also reduce all-cause and cardiovascular mortality. Most older adults (mean age, 75 years) with prediabetes do not progress to diabetes. Among patients in this age group with type 2 diabetes treated with medication, an A1C level of less than 7% is associated with increased risk of...
Source: American Family Physician - July 15, 2022 Category: Primary Care Authors: Mark H Ebell Roland Grad Source Type: research
